Ep. 29: Faron Pharmaceuticals Executives on Cell Therapy Technologies
In this episode, VibeCast host Ray Dogum speaks with Marie Louise Fjallskog & Markku Jalkanen, PhD from Faron Pharmaceuticals about Cell Therapy Technologies. ------------------------------------------------------------------------ Guest Bios: Dr. Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development. She joined Faron from Sensei Biotherapeutics (SNSE), a Nasdaq listed immuno-oncology company. As Chief Medical Officer at Sensei, she was responsible for leading clinical and development strategy and operations. She also played a key role in Sensei’s successful $152 million IPO, which closed in February 2021. Previously, she served as Vice President, Clinical Development at Merus (MRUS) and Infinity Pharmaceuticals (INFI) where she led development of multiple small molecule and immuno-oncology clinical programs. She was formerly Global Clinical Program Leader at the Novartis Institute for Biomedical Research where she led global development of oncology treatments targeting CDK4/6, BCL-2, PD-1, CSF-1 and CD73. Dr. Fjällskog holds both a Ph.D and an M.D. from Uppsala University, Sweden where she currently serves as an Associate Professor of Oncology Dr. Fjällskog also serves on the Board of Biovica, a Swedish biotech company focused on predicting the efficacy of cancer therapies via novel blood-based diagnostics and Lytix Biopharma, a clinical stage biotech developing novel cancer immunotherapies based on pioneering research in host defense peptides. Dr. Markku Jalkanen has more than 30 years of experience within biomedical research, biotech development and the biopharmaceutical industry. He was a founding member of the Company and is its CEO. In addition to his role as CEO, he is an advisor for the only active Finnish life sciences fund, Inveni Capital. Between 1996 and 2002, Dr. Jalkanen was the founding CEO and President of BioTie Therapies Corporation, which become the first publicly traded Finnish biotech company in Helsinki to become listed on the US NASDAQ. Dr. Jalkanen has published more than 130 peer reviewed scientific publications in various highly ranked international journals. Guest Links: Marie Lousie Fjallskog Linkedin: https://www.linkedin.com/in/marie-louise-fj%C3%A4llskog-93847710/ Markku Jalkanen, PhD Linkedin: https://www.linkedin.com/in/markku-jalkanen-417a804/ Faron Pharma Website: https://www.faron.com/ About VibeCast VibeCast is our weekly informational podcast and content series exploring the hottest topics in drug development and Web3 with some of the dynamic people that make up the Vibe community. VibeCast is a collection of long-form and short-form video content intended to help our community learn about the current opportunities and challenges in biotech fundraising and community engagement innovation. Guests will include biotech founders, regulatory experts, drug development executives, blockchain technologists, web3 community builders, patient community advocates, and many other Vibe Bio community members seeking to accelerate the development of breakthrough treatments. Follow Vibe Bio's Socials: https://twitter.com/VibeBio https://www.linkedin.com/company/vibe-bio/ https://www.instagram.com/vibebiotechnology/ https://www.tiktok.com/@vibebio https://www.facebook.com/VibeBiotechnology/ Disclaimer: VibeCast is intended to be used for educational and entertainment purposes, and no information or opinions shared constitute advice or services. While guests are invited to listen, listeners acknowledge they are not being provided professional advice from the podcast or the guests. The podcast is for private non-commercial use and the statements of our guests reflect their personal views only and do not necessarily reflect the views or positions of any agency, organization, or company that they work for or are affiliated with.
